<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5c087e28-0b1f-4ab1-b883-673d5d871d60"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.</content>
      <br/>
      <content styleCode="bold">ATROPINE SULFATE INJECTION, for intravenous use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1960</content>
   </title>
   <effectiveTime value="20250417"/>
   <setId root="d4839e54-b350-4643-8e6e-f0437f5349d6"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="012430880" root="1.3.6.1.4.1.519.1"/>
            <name>Henry Schein, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5b14ca75-abae-434a-bda5-a8a725b852f3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20240419"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0404-9823" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atropine Sulfate
								</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atropine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0409-9630" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.05" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Atropine Sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Atropine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43204" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0404-9823-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220109"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021146" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38208" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ENDOTRACHEAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L90942250-2f5d-49dc-9647-ea47a440a51d">
               <id root="c476d483-dd54-4355-90e3-5e1d35a250af"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Atropine Sulfate Injection is indicated for temporary blockade of severe or life-threatening muscarinic<br/>effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic<br/>mushroom poisoning, and to treat bradyasystolic cardiac arrest.</paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life-threatening muscarinic effects. (1)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L691bc7a8-6ef0-4252-8a66-cd8e93d7a821">
               <id root="f777efea-7c2a-4f97-87ef-f845439d0623"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">2.1 General Administration</content>
                     <br/>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to<br/>administration, whenever solution and container permit. Do not administer unless solution is clear and<br/>seal is intact. Each syringe is intended for single dose only. Discard unused portion.<br/>For intravenous administration.<br/>Titrate based on heart rate, PR interval, blood pressure and symptoms.</paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">2.2 Adult Dosage</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L175ffc5b-b51d-4870-bdd0-c66d1b1ae90d"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2.3 Pediatric Dosage</content>
                  </paragraph>
                  <paragraph>Dosing in pediatric populations has not been well studied. Usual initial dose is 0.01 to 0.03 mg/kg.<br/>
                     <content styleCode="bold">2.4 Dosing in Patients with Coronary Artery Disease</content>
                  </paragraph>
                  <paragraph>Limit the total dose of atropine sulfate to 0.03 mg/kg to 0.04 mg/kg [see Warnings and Precautions (5.1)]</paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• For intravenous administration (2.1)<br/>• Titrate according to heart rate, PR interval, blood pressure and<br/>symptoms (2.1)<br/>• Adult dosage<br/>- Antisialagogue or for antivagal effects: Initial single dose of 0.5 mg to<br/>1 mg (2.2)<br/>- Antidote for organophosphorus or muscarinic mushroom poisoning:<br/>Initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes (2.2)<br/>- Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if<br/>asystole persists (2.2)<br/>• Patients with Coronary Artery Disease: Limit the total dose to 0.03 mg/kg<br/>to 0.04 mg/kg (2.4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="L175ffc5b-b51d-4870-bdd0-c66d1b1ae90d">
                     <text>Image1.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf3fce6b8-c6e8-4705-b3ea-6a3f277c7a0e">
               <id root="18010e84-ef6e-41ea-a1f9-cccde4dfba96"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Injection: 0.05 mg/mL and 0.1 mg/mL in Ansyr® Plastic Syringe.</paragraph>
                  <paragraph>Injection: 0.1 mg/mL in LifeShield® Abboject® Glass Syringe.</paragraph>
                  <paragraph>Injection: 0.1 mg/mL in Abboject® Syringe with Male Luer Lock Adapter.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• 0.05 mg/mL injection in Ansyr® Plastic Syringe (3)<br/>• 0.1 mg/mL injection in Ansyr® Plastic Syringe (3)<br/>• 0.1 mg/mL injection in LifeShield® Abboject® Glass Syringe (3)<br/>• 0.1 mg/mL injection in Abboject® Syringe with Male Luer Lock Adapter (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L1bec79b4-7506-4ca8-a0a0-b2c3892049b9">
               <id root="e5e94748-fcff-468c-8483-fbf5596c6f64"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L212c8ead-db62-4c48-be3f-088de79f6c65">
               <id root="7de53c8c-11de-4f5e-93b4-922bdac0828e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">5.1 Tachycardia</content>
                     <br/>When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose<br/>should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of<br/>atropine-induced tachycardia on myocardial oxygen demand.<br/>
                     <content styleCode="bold">5.2 Acute Glaucoma</content>
                     <br/>Atropine may precipitate acute glaucoma.</paragraph>
                  <paragraph>
                     <content styleCode="bold">5.3 Pyloric Obstruction</content>
                     <br/>Atropine may convert partial organic pyloric stenosis into complete obstruction.<br/>
                     <content styleCode="bold">5.4 Complete Urinary Retention</content>
                     <br/>Atropine may lead to complete urinary retention in patients with prostatic hypertrophy.<br/>
                     <content styleCode="bold">5.5 Viscid Plugs</content>
                     <br/>Atropine may cause inspissation of bronchial secretions and formation of viscid plugs in patients with<br/>chronic lung disease.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Tachycardia (5.1)<br/>• Glaucoma (5.2)<br/>• Pyloric obstruction (5.3)<br/>• Worsening urinary retention (5.4)<br/>• Viscid bronchial plugs (5.5)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Lc551883c-98cc-4a99-b7ef-3dd78cbf7b1f">
               <id root="6bca34cd-6c79-433e-9dd2-7dbfe4d031a2"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following adverse reactions have been identified during post-approval use of atropine sulfate.<br/>Because these reactions are reported voluntarily from a population of uncertain size, it is not always<br/>possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br/>Most of the side effects of atropine are directly related to its antimuscarinic action. Dryness of the mouth,<br/>blurred vision, photophobia and tachycardia commonly occur. Anhidrosis can produce heat intolerance.<br/>Constipation and difficulty in micturition may occur in elderly patients. Occasional hypersensitivity<br/>reactions have been observed, especially skin rashes which in some instances progressed to exfoliation.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most adverse reactions are directly related to atropine’s antimuscarinic action.<br/>Dryness of the mouth, blurred vision, photophobia and tachycardia commonly<br/>occur with chronic administration of therapeutic doses. (6)</paragraph>
                        <paragraph>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Lcf1d5b68-2487-498a-aef5-9ac3fb08c8a4">
               <id root="dc707918-5a99-4b2c-93cd-244ba0d88715"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">7.1 Mexiletine</content>
                  </paragraph>
                  <paragraph>Atropine Sulfate Injection decreased the rate of mexiletine absorption without altering the relative oral<br/>bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and<br/>intravenous metoclopramide during pretreatment for anesthesia.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mexiletine Decreases rate of mexiletine absorption. (7.1)<br/>
                           <content styleCode="bold">Revised: 11/2020</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L4609f0fc-cdca-4c9a-ade5-087b342a70fb">
               <id root="ba893e78-247a-495a-af29-6a9289c3cf22"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">8.1 Pregnancy</content>
                     <br/>Animal reproduction studies have not been conducted with atropine. It also is not known whether atropine<br/>can cause fetal harm when given to a pregnant woman or can affect reproduction capacity.<br/>
                     <content styleCode="bold">8.3 Nursing Mothers</content>
                     <br/>Trace amounts of atropine was found in breast milk. The clinical impact of this is not known.<br/>
                     <content styleCode="bold">8.4 Pediatric Use</content>
                     <br/>Recommendations for use in pediatric patients are not based on clinical trials.<br/>
                     <content styleCode="bold">8.5 Geriatric Use</content>
                     <br/>An evaluation of current literature revealed no clinical experience identifying differences in response<br/>between elderly and younger patients. In general, dose selection for an elderly patient should be cautious,<br/>usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,<br/>renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
            </section>
         </component>
         <component>
            <section ID="L5fa0d389-2b57-45de-ad55-2bf2b27cb5f1">
               <id root="38cc07db-f164-41ab-b81e-e6202ed3f218"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Excessive dosing may cause palpitation, dilated pupils, difficulty in swallowing, hot dry skin, thirst,<br/>dizziness, restlessness, tremor, fatigue and ataxia. Toxic doses lead to restlessness and excitement,<br/>hallucinations, delirium and coma. Depression and circulatory collapse occur only with severe<br/>intoxication. In such cases, blood pressure declines and death due to respiratory failure may ensue<br/>following paralysis and coma.<br/>The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal.<br/>In the event of toxic overdosage, a short acting barbiturate or diazepam may be given as needed to control<br/>marked excitement and convulsions. Large doses for sedation should be avoided because central<br/>depressant action may coincide with the depression occurring late in atropine poisoning. Central<br/>stimulants are not recommended.<br/>Physostigmine, given as an atropine antidote by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in<br/>pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since<br/>physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and<br/>repeated doses may be required.<br/>Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever,<br/>especially in pediatric populations.<br/>Atropine is not removed by dialysis</paragraph>
               </text>
               <effectiveTime value="20250418"/>
            </section>
         </component>
         <component>
            <section ID="Lcb70afb3-eab8-4e18-8ac1-168453f2e4e3">
               <id root="9bc3351c-b94a-49c6-bd71-d01d344397ff"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine sulfate<br/>monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is<br/>administered parenterally by intravenous injection.<br/>Each milliliter (mL) contains 0.1 mg (adult strength) or 0.05 mg (pediatric strength) of atropine sulfate<br/>monohydrate equivalent to 0.083 mg (adult strength) or 0.042 mg (pediatric strength) of atropine, and<br/>sodium chloride, 9 mg. May contain sodium hydroxide and/or sulfuric acid for pH adjustment<br/>0.308 mOsmol/mL (calc.). pH 3.0 to 6.5.<br/>Sodium chloride added to render the solution isotonic for injection of the active ingredient is present in<br/>amounts insufficient to affect serum electrolyte balance of sodium (Na+<br/>) and chloride (Cl-<br/>) ions.<br/>The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and<br/>is intended for use only as a single-dose injection. When smaller doses are required the unused portion<br/>should be discarded.<br/>Atropine Sulfate, USP is chemically designated 1α H, 5α H-Tropan-3-α-ol (±)-tropate (ester), sulfate (2:1)<br/>(salt) monohydrate, (C<sub>17</sub>H<sub>23</sub>NO<sub>3</sub>)<sub>2</sub> H<sub>2</sub>SO<sub>4</sub> H<sub>2</sub>O, colorless crystals or white crystalline powder very<br/>soluble in water. It has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L6d612fd1-4716-4652-99e7-8dfe5f06a15b"/>
                  </paragraph>
                  <paragraph>Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and<br/>1-hyocyamine, whose activity is due almost entirely to the levo isomer of the drug.<br/>Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.<br/>The Ansyr® syringe is molded from a specially formulated polypropylene. Water permeates from inside<br/>the container at an extremely slow rate which will have an insignificant effect on solution concentration<br/>over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical<br/>components from the plastic in very small amounts; however, biological testing was supportive of the<br/>safety of the syringe material</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <observationMedia ID="L6d612fd1-4716-4652-99e7-8dfe5f06a15b">
                     <text>Formula1.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Formula1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L8b630aa1-2c6a-4154-8fd2-3ca4ce6871d7">
               <id root="b3bc0e45-617a-4131-962d-0212365dbb33"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">12.1 Mechanism of Action</content>
                     <br/>Atropine is an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and<br/>other choline esters.<br/>Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic<br/>cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so<br/>innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or<br/>surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at<br/>receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic<br/>destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are<br/>stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to<br/>postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily<br/>than with responses to injected (exogenous) choline esters.<br/>
                     <content styleCode="bold">12.2 Pharmacodynamics</content>
                     <br/>Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation,<br/>especially on the heart where small doses first slow the rate before characteristic tachycardia develops due<br/>to paralysis of vagal control. Atropine exerts a more potent and prolonged effect on heart, intestine and<br/>bronchial muscle than scopolamine, but its action on the iris, ciliary body and certain secretory glands is<br/>weaker than that of scopolamine. Unlike the latter, atropine in clinical doses does not depress the central<br/>nervous system but may stimulate the medulla and higher cerebral centers. Although mild vagal excitation<br/>occurs, the increased respiratory rate and (sometimes) increased depth of respiration produced by atropine<br/>are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory<br/>stimulant and large or repeated doses may depress respiration.<br/>Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug<br/>also prevents or abolishes bradycardia or asystole produced by injection of choline esters,</paragraph>
                  <paragraph>anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation<br/>of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic<br/>factor. In some patients with complete heart block, the idioventricular rate may be accelerated by atropine;<br/>in others, the rate is stabilized. Occasionally a large dose may cause atrioventricular (A-V) block and<br/>nodal rhythm.<br/>Atropine Sulfate Injection in clinical doses counteracts the peripheral dilatation and abrupt decrease in<br/>blood pressure produced by choline esters. However, when given by itself, atropine does not exert a<br/>striking or uniform effect on blood vessels or blood pressure. Systemic doses slightly raise systolic and<br/>lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly<br/>increase cardiac output and decrease central venous pressure. Occasionally, therapeutic doses dilate<br/>cutaneous blood vessels, particularly in the “blush” area (atropine flush) and may cause atropine “fever”<br/>due to suppression of sweat gland activity in infants and small children.<br/>The effects of intravenous atropine on heart rate (maximum heart rate) and saliva flow (minimum flow)<br/>after intravenous administration (rapid, constant infusion over 3 min.) are delayed by 7 to 8 minutes after<br/>drug administration and both effects are non-linearly related to the amount of drug in the peripheral<br/>compartment. Changes in plasma atropine levels following intramuscular administration (0.5 to<br/>4 mg doses) and heart rate are closely overlapped but the time course of the changes in atropine levels and<br/>behavioral impairment indicates that pharmacokinetics is not the primary rate-limiting mechanism for the<br/>central nervous system effect of atropine.<br/>
                     <content styleCode="bold">12.3 Pharmacokinetics</content>
                     <br/>Atropine disappears rapidly from the blood following injection and is distributed throughout the body.<br/>Exercise, both prior to and immediately following intramuscular administration of atropine, significantly<br/>increases the absorption of atropine due to increased perfusion in the muscle and significantly decreases<br/>the clearance of atropine. The pharmacokinetics of atropine is nonlinear after intravenous administration<br/>of 0.5 to 4 mg. Atropine’s plasma protein binding is about 44% and saturable in the 2-20 μg/mL<br/>concentration range. Atropine readily crosses the placental barrier and enters the fetal circulation, but is<br/>not found in amniotic fluid. Much of the drug is destroyed by enzymatic hydrolysis, particularly in the<br/>liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including<br/>milk. The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. The<br/>metabolism of atropine is inhibited by organophosphate pesticides.<br/>
                     <content styleCode="bold">Specific Populations</content>
                     <br/>The elimination half-life of atropine is more than doubled in children under two years and the elderly<br/>(&gt;65 years old) compared to other age groups. There is no gender effect on the pharmacokinetics and<br/>pharmacodynamics (heart rate changes) of atropine.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
            </section>
         </component>
         <component>
            <section ID="L65e52619-9487-4bd0-bed0-0b65dbc47280">
               <id root="7eb4b258-2906-4ab8-ad4f-ec43cc145bc1"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     <br/>Studies have not been performed to evaluate the carcinogenic or mutagenic potential of atropine or its<br/>potential to affect fertility adversely.</paragraph>
               </text>
               <effectiveTime value="20250418"/>
            </section>
         </component>
         <component>
            <section ID="L1979ba04-bb78-472f-b77d-71aee51491f0">
               <id root="3faa5d85-30f0-4318-97a3-b5fa41b301b6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Atropine Sulfate Injection, USP is supplied in single-dose syringes as follows:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld5d26561-896a-4e5a-a563-7d09245da8fa"/>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).<br/>[See USP Controlled Room Temperature.]</paragraph>
                  <table width="100%">
                     <caption> Product repackaged by: Henry Schein, Inc., Bastian, VA 24314</caption>
                     <tbody>
                        <tr>
                           <td>From Original Manufacturer/Distributor's NDC and Unit of Sale</td>
                           <td>To Henry Schein Repackaged Product NDC and Unit of Sale</td>
                           <td>Total Strength/Total Volume (Concentration) per unit</td>
                        </tr>
                        <tr>
                           <td>NDC 0409-9630-05<br/>Bundle of 10<br/>Ansyr™ Plastic Syringe</td>
                           <td>NDC 0404-9823-05<br/>1 Ansyr™ Plastic Syringe in a bag<br/>(Vial bears NDC 0409-9630-15)</td>
                           <td>Concentration: 0.05 mg/mL<br/>Fill Volume: 5 mL<br/>Total Atropine Content: 0.25 mg</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA<br/>Abboject® is a trademark of Abbott Laboratories.<br/>LifeShield® is the trademark of ICU Medical, Inc. and is used under license.</paragraph>
                  <paragraph>LAB-1041-4.2</paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <observationMedia ID="Ld5d26561-896a-4e5a-a563-7d09245da8fa">
                     <text>Image2.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L521ff54d-d711-499f-9e36-abc788511197">
               <id root="1fa04339-3e26-4d19-a30b-0a0977bbc412"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>SAMPLE PACKAGE LABEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lac86bb53-fa0f-4ed0-9e52-9d0613c1b2fe"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <observationMedia ID="Lac86bb53-fa0f-4ed0-9e52-9d0613c1b2fe">
                     <text>Label1.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Label1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>